Correspondence 0001193125-23-263644 from EyePoint Pharmaceuticals, Inc. (EYPT) (CIK 0001314102) (EYPT)
EyePoint Pharmaceuticals, Inc. (EYPT) (CIK 0001314102)
Date: Oct. 26, 2023 · CIK: 0001314102 · Accession: 0001193125-23-263644
AI Filing Summary & Sentiment
File numbers found in text: 333-275125
Letter
VIA EDGAR Division of Corporation Finance Registration Statement on Form S-3 Filed October 20, 2023 File No. 333-275125 Request for Acceleration of Effective Date
Dear Jane Park:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, EyePoint Pharmaceuticals, Inc. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3 and declare such Registration Statement effective as of 4:00 p.m., Eastern Time, on October 30, 2023, or as soon thereafter as possible.
Please direct any questions or comments concerning this request to Stephen M. Nicolai of Hogan Lovells US LLP at (267) 675-4642. Also, please notify Mr. Nicolai when this request for acceleration has been granted.
Very truly yours,
EyePoint Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP EYEPOINT PHARMACEUTICALS, INC. 480 Pleasant Street Watertown, MA 02472 October 26, 2023 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Jane Park Re: EyePoint Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed October 20, 2023 File No. 333-275125 Request for Acceleration of Effective Date Dear Jane Park: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, EyePoint Pharmaceuticals, Inc. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3 and declare such Registration Statement effective as of 4:00 p.m., Eastern Time, on October 30, 2023, or as soon thereafter as possible. Please direct any questions or comments concerning this request to Stephen M. Nicolai of Hogan Lovells US LLP at (267) 675-4642. Also, please notify Mr. Nicolai when this request for acceleration has been granted. Very truly yours, EyePoint Pharmaceuticals, Inc. By: /s/ Ron Honig Name: Ron Honig Title: Chief Legal Officer